Brian Canann, Managing Director, NaviMed Capital, a Washington, DC based venture capital firm focused on revenue-stage healthcare investments. Prior to co-founding NaviMed Capital, he was a healthcare investment professional at The Carlyle Group.
He also led the global marketing effort for the Endeavor drug-eluting stent development program at Medtronic. Mr. Canann held various strategic planning and global product management positions in the critical care division of Edwards Lifesciences, the global leader in heart valves and hemodynamic monitoring. He was also a CPA in the Boston office of Price Waterhouse. .
Mr. Canann is on the Board of Directors of Elenza. He is a Board Observer of AqueSys and PixelOptics. He previously served on the Board of Directors of Carefx (sold to Harris), the HealthCentral Network and Primary Health (sold to PacificSource Health Plans) and as a Board Observer of Endius (sold to Zimmer). He holds a M.S. and a B.S. on accounting from Brigham Young University and an M.B.A. from Harvard Business School.